Hospital
Adventist Health Medical Center Tehachapi
Adventist Health Medical Center Tehachapi was paid $17.97M by Medicaid between Jan 2018 and Dec 2024, across 233 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoADVENTIST HEALTH MEDICAL CENTER TEHACHAPI
TEHACHAPI, CA 93561
TEHACHAPI, CA 93561
33aNPI1275538530assigned 06/14/2005
33bProvider typeCritical Access Hospital
28Total paid$17.97M
24GClaims481,112
24DCodes billed233
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#3 of 30
Median peer was paid$3.14M
This provider vs. median5.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,448 | $1.46M | |
| 2019 | 68,119 | $1.93M | |
| 2020 | 48,487 | $1.37M | |
| 2021 | 56,100 | $1.81M | |
| 2022 | 80,466 | $3.13M | |
| 2023 | 91,413 | $4.35M | |
| 2024incomplete | 84,079 | $3.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 15,368 | 13,991 | $5.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 15,638 | 13,053 | $4.35M |
| 0450 | Emergency room services | 7.7% | 17,187 | 15,530 | $1.38M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.1% | 1,155 | 1,061 | $1.10M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 9,207 | 2,692 | $371K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 2,837 | 2,592 | $314K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 9,172 | 8,002 | $223K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,594 | 3,282 | $177K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,208 | 2,156 | $168K |
| 80053 | Comprehensive metabolic panel | <1% | 25,544 | 22,814 | $156K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,357 | 2,090 | $151K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,539 | 7,290 | $138K |
221 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29,818 | $131K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,286 | $128K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,709 | $122K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,238 | $119K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,476 | $113K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,195 | $108K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,197 | $106K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,489 | $105K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,705 | $101K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,413 | $96K |
| 71045 | Radiologic examination, chest; single view | <1% | 17,595 | $95K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,214 | $88K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,226 | $88K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,578 | $87K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 285 | $82K |
| 80061 | Lipid panel | <1% | 7,316 | $81K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 83 | $73K |
| Z7502 | <1% | 1,759 | $65K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,751 | $64K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 694 | $63K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,988 | $57K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,267 | $53K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,518 | $52K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,278 | $51K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,175 | $50K |
| 76830 | Ultrasound, transvaginal | <1% | 1,066 | $47K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 647 | $41K |
| 81001 | <1% | 18,889 | $40K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 1,244 | $40K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 931 | $40K |
| 80074 | <1% | 1,059 | $36K | |
| 83880 | <1% | 3,019 | $33K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,009 | $33K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,618 | $32K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 344 | $32K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,838 | $32K |
| 84484 | <1% | 8,164 | $29K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,391 | $28K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,174 | $26K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,176 | $26K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,227 | $26K |
| J3490 | Unclassified drugs | <1% | 6,300 | $26K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,028 | $25K |
| 0270 | <1% | 5,411 | $25K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,619 | $22K |
| 73030 | <1% | 1,149 | $22K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,765 | $22K |
| 83735 | <1% | 5,993 | $21K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,983 | $21K |
| 76801 | <1% | 748 | $21K | |
| 83690 | <1% | 7,272 | $20K | |
| 84439 | <1% | 2,427 | $20K | |
| 97116 | <1% | 1,323 | $19K | |
| 97162 | <1% | 200 | $18K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,077 | $18K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,278 | $17K |
| 71250 | <1% | 130 | $16K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,889 | $16K |
| 73630 | <1% | 1,134 | $15K | |
| 73562 | <1% | 1,091 | $15K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,516 | $15K |
| 73564 | <1% | 332 | $14K | |
| 0762 | <1% | 34 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 520 | $14K |
| 87040 | <1% | 3,788 | $13K | |
| 81025 | <1% | 4,996 | $13K | |
| 83605 | <1% | 3,886 | $13K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,488 | $12K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,086 | $12K |
| 99199 | Unlisted special service, procedure or report | <1% | 234 | $11K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,268 | $11K |
| 87186 | <1% | 2,468 | $10K | |
| 0360 | <1% | 223 | $10K | |
| 73130 | <1% | 747 | $10K | |
| 73610 | <1% | 710 | $10K | |
| 85730 | <1% | 3,283 | $10K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 426 | $9K |
| 85610 | <1% | 4,694 | $9K | |
| 87400 | <1% | 3,482 | $9K | |
| 76536 | <1% | 141 | $8K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 119 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 25 | $7K |
| 85379 | <1% | 1,430 | $7K | |
| 86038 | <1% | 618 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,545 | $7K |
| 82043 | <1% | 1,286 | $7K | |
| 87077 | <1% | 1,954 | $6K | |
| 72100 | <1% | 380 | $6K | |
| 99070 | <1% | 19,243 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 189 | $6K |
| 93971 | <1% | 120 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 38 | $5K |
| 86592 | <1% | 1,265 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,288 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 456 | $5K |
| 80076 | <1% | 1,414 | $5K | |
| 82728 | <1% | 352 | $5K | |
| 94664 | <1% | 1,318 | $5K | |
| 73110 | <1% | 245 | $5K | |
| 84703 | <1% | 1,127 | $5K | |
| 84100 | <1% | 991 | $4K | |
| 87081 | <1% | 2,169 | $4K | |
| 99442 | <1% | 52 | $4K | |
| 82150 | <1% | 1,370 | $4K | |
| 84702 | <1% | 679 | $4K | |
| 73502 | <1% | 94 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 27 | $4K |
| 82607 | <1% | 248 | $4K | |
| 74018 | <1% | 503 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,294 | $3K |
| 86140 | <1% | 809 | $3K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 51 | $3K |
| 72110 | <1% | 118 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,266 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 100 | $3K |
| 83540 | <1% | 473 | $3K | |
| 76641 | <1% | 40 | $3K | |
| 84481 | <1% | 196 | $3K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 12 | $3K |
| 85652 | <1% | 957 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $3K |
| 74022 | <1% | 194 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 728 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 69 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 919 | $2K |
| 86780 | <1% | 230 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 544 | $2K |
| 90686 | <1% | 167 | $2K | |
| 90715 | <1% | 158 | $2K | |
| 82550 | <1% | 834 | $2K | |
| 70496 | <1% | 12 | $2K | |
| 82553 | <1% | 508 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 788 | $2K |
| 96367 | <1% | 134 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 64 | $1K |
| 82570 | <1% | 262 | $1K | |
| 82962 | <1% | 1,136 | $1K | |
| 0259 | <1% | 108 | $1K | |
| 82948 | <1% | 854 | $1K | |
| 87807 | <1% | 584 | $1K | |
| 94760 | <1% | 150 | $1K | |
| 82248 | <1% | 550 | $1K | |
| 84550 | <1% | 239 | $1K | |
| 76642 | <1% | 12 | $1K | |
| 96376 | <1% | 71 | $1K | |
| 82746 | <1% | 76 | $1K | |
| 72040 | <1% | 68 | $974.95 | |
| 86431 | <1% | 204 | $920.14 | |
| 70498 | <1% | 12 | $840.82 | |
| 84153 | <1% | 49 | $838.21 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 450 | $832.27 |
| 83615 | <1% | 507 | $826.23 | |
| 90658 | <1% | 77 | $821.46 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 263 | $817.46 |
| 87430 | <1% | 358 | $756.45 | |
| 85651 | <1% | 443 | $756.29 | |
| 84436 | <1% | 140 | $697.24 | |
| Z7610 | <1% | 291 | $668.65 | |
| 71010 | <1% | 39 | $640.31 | |
| 85027 | <1% | 267 | $629.92 | |
| 83970 | <1% | 13 | $624.64 | |
| 86901 | <1% | 289 | $614.79 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 16 | $590.00 |
| A4217 | Sterile water/saline, 500 ml | <1% | 440 | $549.82 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 760 | $547.23 |
| 86900 | <1% | 290 | $522.53 | |
| 84479 | <1% | 114 | $503.54 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 177 | $490.89 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 117 | $485.48 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 312 | $481.14 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 262 | $458.06 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,028 | $420.96 |
| 97161 | <1% | 35 | $420.12 | |
| 0250 | <1% | 84 | $407.49 | |
| 84403 | <1% | 14 | $385.20 | |
| 86694 | <1% | 25 | $373.19 | |
| 74019 | <1% | 26 | $373.17 | |
| 73080 | <1% | 26 | $342.82 | |
| 82140 | <1% | 49 | $334.53 | |
| 92552 | <1% | 14 | $305.20 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $301.84 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12 | $296.02 |
| S1016 | Non-pvc (polyvinyl chloride) intravenous administration set, for use with drugs that are not stable in pvc e.g., paclitaxel | <1% | 628 | $294.54 |
| 80143 | <1% | 38 | $284.64 | |
| 86376 | <1% | 12 | $213.80 | |
| 87070 | <1% | 45 | $173.26 | |
| 86701 | <1% | 26 | $164.03 | |
| 86430 | <1% | 38 | $157.62 | |
| 85007 | <1% | 116 | $156.52 | |
| 70486 | <1% | 13 | $151.96 | |
| 80305 | <1% | 27 | $151.44 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 39 | $143.84 |
| 84154 | <1% | 12 | $138.87 | |
| 84480 | <1% | 12 | $138.45 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 12 | $131.93 |
| 73590 | <1% | 13 | $127.75 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 14 | $115.00 |
| 99001 | <1% | 446 | $111.15 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 29 | $93.09 |
| 73140 | <1% | 12 | $85.10 | |
| J2704 | Injection, propofol, 10 mg | <1% | 253 | $77.40 |
| 86756 | <1% | 28 | $64.89 | |
| 0710 | <1% | 55 | $53.82 | |
| 87205 | <1% | 26 | $42.50 | |
| 82805 | <1% | 13 | $30.58 | |
| 90630 | <1% | 12 | $29.26 | |
| 84145 | <1% | 16 | $22.21 | |
| 81003 | <1% | 82 | $16.09 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12 | $9.72 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 18 | $5.16 |
| S0028 | Injection, famotidine, 20 mg | <1% | 32 | $0.94 |
| 1159F | 0% | 1,224 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 62 | $0.00 |
| 1160F | 0% | 1,016 | $0.00 | |
| 3078F | 0% | 95 | $0.00 | |
| 3077F | 0% | 48 | $0.00 | |
| 3008F | 0% | 877 | $0.00 | |
| 80320 | 0% | 31 | $0.00 | |
| 3074F | 0% | 68 | $0.00 | |
| 3079F | 0% | 38 | $0.00 | |
| 3075F | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELLS, JASON (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| San Joaquin Community Hospital | Bakersfield, CA | $107.31M |
| Adventist Health Medical Center Tehachapi | Mojave, CA | $4.47M |
| Adventist Health Medical Center Tehachapi | Tehachapi, CA | $3.98M |
| Adventist Health Medical Center Tehachapi | California City, CA | $3.93M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.